Clarity’s new “pan-cancer” radiopharmaceutical
Clarity Pharmaceuticals (ASX:CU6) has expanded its cancer treatment pipeline with the development of a novel radiopharmaceutical called “SAR-bisFAP”. This new product is designed for both diagnosis and treatment, and has possible “pan-cancer opportunity”. What’s in a name? Radiopharmaceuticals combine two components: a radioactive isotope and a targeting molecule. The targeting molecule directs the isotope to […]
Clarity’s new “pan-cancer” radiopharmaceutical Read More »






